A Randomized, Double-Blind, Vehicle-Controlled, 3-Period, Sequential Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Repeat Topical Applications of GSK2894512 Cream in Healthy Adult Participants
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Benvitimod (Primary)
- Indications Atopic dermatitis; Inflammatory bowel diseases; Plaque psoriasis; Psoriasis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 05 Sep 2017 Planned End Date changed from 27 Aug 2018 to 15 May 2018.
- 05 Sep 2017 Planned primary completion date changed from 27 Aug 2018 to 15 May 2018.
- 05 Sep 2017 Planned initiation date changed from 12 Feb 2018 to 14 Dec 2017.